Authors
Latest:
Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCNAndrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.
Latest:
PD-1 Blockade and Transplant as a Potential New Treatment in PTCLMwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.
Latest:
Exploring the Importance of Finding a Molecular Target in Lung CancerBrendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.
Latest:
Key Takeaways on Recent Data in Multiple Myeloma from ASH 2023Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.
Latest:
Liquid Biopsy Holds Promise in Prostate Cancer DiagnosisAccording to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.
Latest:
Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel TherapiesDespite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.
Latest:
Study Investigators Question the Rise of CRC in Young Adult PatientsAmir Khan, MD, discusses the possible reasons for the rising incidence of young adult patients with gastric cancer and colorectal cancer at the 2020 Gastrointestinal Cancers Symposium.
Latest:
Metastatic Endometrial Cancer: Future Directions in CareClosing out her discussion on the management of recurrent metastatic endometrial cancer, Bhavana Pothuri, MD, highlights ongoing clinical trials and novel treatment modalities.
Latest:
Survival Benefit Shown With Niraparib Plus Abiraterone in BRCA+ mCRPCAdding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Latest:
Polatuzumab Vedotin Plus R-CHOP May Improve Outcomes For DLBCL PatientsThomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.
Latest:
Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian CancerLucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.
Latest:
Research Ongoing for CAR T-Cell Therapy Axi-Cel in LymphomaSairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.
Latest:
Germline Testing Outside the Guidelines: Can it Address Health Disparities?The completion of the Human Genome project has ushered in a new era in our understanding of cancer.
Latest:
What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.
Latest:
Pirtobrutinib Produces Durable Responses in Pretreated MCLNirav Shah, MD, discusses long-term data from the phase 1/2 BRUIN study which evaluated pirtobrutinib in mantle cell lymphoma, and next steps for evaluating the agent.
Latest:
Ide-cel Significantly Prolongs PFS in KarMMa-3 Trial for Multiple MyelomaPaula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.
Latest:
Astsaturov on the Phase 1 Study of LP-184 in Advanced Solid TumorsIgor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.
Latest:
Vano Highlights Trials and Data in RCCYann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.
Latest:
Anticipating Expanded Uses of Radiotherapy in Urothelial CarcinomaSophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.
Latest:
Challenges of Breast Cancer in Young AdultsAccording to Jane Méndez, M.D., FACS, special considerations come into play when diagnosing and treating young adults with breast cancer.
Latest:
NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over ChemotherapyLeora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.
Latest:
Steroid-Refractory cGvHD: Emerging Treatment OptionsThis segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Choosing Second-Line Therapy for HCC After Atezolizumab/BevacizumabDaneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.
Latest:
PARP Inhibitor-Resistant Ovarian Cancer Responds to PARP Plus ATR InhibitorsStephanie L. Wethington, MD, MSc, discusses results of a study of olaparib plus ceralasertib for overcoming resistance to PARP inhibition.
Latest:
Managing Toxicity Seen With Linvoseltamab in R/R Multiple MyelomaHans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.
Latest:
Unmet Needs for Managing CRS and ICANS Due to CAR T-Cell TherapyNicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.
